{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T04:27:43Z","timestamp":1741667263076,"version":"3.38.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00120-025-02526-4","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:54:18Z","timestamp":1740149658000},"page":"237-245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radionuklidtherapie 2025: Optionen der Nuklearmedizin in der Behandlung des metastasierten kastrationsresistenten Prostatakarzinoms","Radionuclide therapy in 2025: nuclear medicine options in the treatment of metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"64","author":[{"given":"Luisa","family":"Willner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"issue":"5","key":"2526_CR1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1053\/j.semnuclmed.2008.05.002","volume":"38","author":"AI Kassis","year":"2008","unstructured":"Kassis\u00a0AI (2008) Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med 38(5):358\u2013366. https:\/\/doi.org\/10.1053\/j.semnuclmed.2008.05.002","journal-title":"Semin Nucl Med"},{"issue":"3","key":"2526_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/1874471011666180502104524","volume":"11","author":"A Morgenstern","year":"2018","unstructured":"Morgenstern\u00a0A et\u00a0al (2018) An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth. Curr Radiopharm 11(3):200\u2013208. https:\/\/doi.org\/10.2174\/1874471011666180502104524","journal-title":"Curr Radiopharm"},{"issue":"2","key":"2526_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1089\/thy.1997.7.163","volume":"7","author":"CT Sawin","year":"1997","unstructured":"Sawin\u00a0CT, Becker\u00a0DV (1997) Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid 7(2):163\u2013176. https:\/\/doi.org\/10.1089\/thy.1997.7.163","journal-title":"Thyroid"},{"issue":"3","key":"2526_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2967\/jnumed.121.262997","volume":"63","author":"AK Miyahira","year":"2022","unstructured":"Miyahira\u00a0AK, Soule\u00a0HR (2022) The History of Prostate-Specific Membrane Antigen as a\u00a0Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation. J\u00a0Nucl Med 63(3):331\u2013338. https:\/\/doi.org\/10.2967\/jnumed.121.262997","journal-title":"J Nucl Med"},{"issue":"4","key":"2526_CR5","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s00268-005-0544-5","volume":"30","author":"Y Kinoshita","year":"2006","unstructured":"Kinoshita\u00a0Y et\u00a0al (2006) Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 30(4):628\u2013636. https:\/\/doi.org\/10.1007\/s00268-005-0544-5","journal-title":"World J Surg"},{"issue":"3","key":"2526_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/pros.21241","volume":"71","author":"S Minner","year":"2011","unstructured":"Minner\u00a0S et\u00a0al (2011) High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 71(3):281\u2013288. https:\/\/doi.org\/10.1002\/pros.21241","journal-title":"Prostate"},{"issue":"2","key":"2526_CR7","doi-asserted-by":"publisher","first-page":"67S","DOI":"10.2967\/jnumed.116.186767","volume":"58","author":"M Eiber","year":"2017","unstructured":"Eiber\u00a0M et\u00a0al (2017) Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. J\u00a0Nucl Med 58(2):67S\u201376S. https:\/\/doi.org\/10.2967\/jnumed.116.186767","journal-title":"J Nucl Med"},{"issue":"1","key":"2526_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar\u00a0K et\u00a0al (2017) German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J\u00a0Nucl Med 58(1):85\u201390. https:\/\/doi.org\/10.2967\/jnumed.116.183194","journal-title":"J Nucl Med"},{"issue":"12","key":"2526_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor\u00a0O et\u00a0al (2021) Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N\u00a0Engl J Med 385(12):1091\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa2107322","journal-title":"N Engl J Med"},{"issue":"10276","key":"2526_CR10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman\u00a0MS et\u00a0al (2021) (177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a\u00a0randomised, open-label, phase\u00a02\u00a0trial. Lancet 397(10276):797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3","journal-title":"Lancet"},{"issue":"10459","key":"2526_CR11","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris\u00a0MJ et\u00a0al (2024) (177)Lu-PSMA-617 versus a\u00a0change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a\u00a0phase\u00a03, randomised, controlled trial. Lancet 404(10459):1227\u20131239. https:\/\/doi.org\/10.1016\/S0140-6736(24)01653-2","journal-title":"Lancet"},{"key":"2526_CR12","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04720157. Zugegriffen: 23. Dez. 2024"},{"issue":"5","key":"2526_CR13","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.ijrobp.2014.12.061","volume":"91","author":"JL Humm","year":"2015","unstructured":"Humm\u00a0JL et\u00a0al (2015) Radium-223 in the treatment of osteoblastic metastases: a\u00a0critical clinical review. Int J Radiat Oncol Biol Phys 91(5):898\u2013906. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.12.061","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2526_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker\u00a0C et\u00a0al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N\u00a0Engl J Med 369(3):213\u2013223. https:\/\/doi.org\/10.1056\/NEJMoa1213755","journal-title":"N Engl J Med"},{"key":"2526_CR15","unstructured":"https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RV_STP\/s-z\/xofigo.html. Zugegriffen: 23. Dez. 2024"},{"key":"2526_CR16","unstructured":"Deutsche Gesellschaft f\u00fcr Urologie e.\u202fV (2024) S3-Leitlinie Prostatakarzinom. Version\u00a07.0. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/043-022OL. Zugegriffen: 23. Dez. 2024"},{"issue":"2","key":"2526_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1.","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge\u00a0MM et\u00a0al (2024) Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a\u00a0multicentre, retrospective study. Lancet Oncol 25(2):175\u2013183. https:\/\/doi.org\/10.1016\/S1470-2045(23)00638-1","journal-title":"Lancet Oncol"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02526-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02526-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02526-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T17:51:57Z","timestamp":1741629117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02526-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2526"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02526-4","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"type":"print","value":"2731-7064"},{"type":"electronic","value":"2731-7072"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"10 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.\u00a0Willner und R.\u00a0Tauber geben an, dass kein Interessenkonflikt besteht. M.\u00a0Eiber berichtet \u00fcber Honorare von Blue Earth Diagnostics Ltd. (Berater, Forschungsfinanzierung), Novartis\/AAA (Berater, Referent), Telix (Berater), Bayer (Berater, Forschungsfinanzierung), RayzeBio (Berater), Point Biopharma (Berater), Eckert-Ziegler (Referent) und Janssen Pharmaceuticals (Berater, Referentenb\u00fcro), Parexel (Bild\u00fcberpr\u00fcfung) und Bioclinica (Bild\u00fcberpr\u00fcfung) au\u00dferhalb der eingereichten Arbeit und einer Patentanmeldung f\u00fcr rhPSMA. Er und andere Erfinder haben Anspruch auf Erl\u00f6se aus dem Verkauf von POSLUMA\u00ae. ME ist Mitglied in Beir\u00e4ten und\/oder Lenkungsaussch\u00fcssen von Novartis, Blue Earth Diagnostics und Telix.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}